A year in review: AN2 Therapeutics Inc (ANTX)’s performance in the last year

While AN2 Therapeutics Inc has underperformed by -0.88%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ANTX fell by -43.22%, with highs and lows ranging from $3.07 to $0.87, whereas the simple moving average fell by -6.50% in the last 200 days.

On August 09, 2024, Leerink Partners Downgraded AN2 Therapeutics Inc (NASDAQ: ANTX) to Market Perform. A report published by Evercore ISI on August 09, 2024, Downgraded its rating to ‘Underperform’ for ANTX. Leerink Partners also Upgraded ANTX shares as ‘Outperform’, setting a target price of $5 on the company’s shares in a report dated July 03, 2024. Leerink Partners February 13, 2024d its ‘Outperform’ rating to ‘Market Perform’ for ANTX, as published in its report on February 13, 2024. JMP Securities also rated the stock as ‘Mkt Perform’.

Analysis of AN2 Therapeutics Inc (ANTX)

To gain a thorough understanding of AN2 Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -49.32% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 8.68, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

It is also very valuable to look at average volume as an indicator of volatility for a stock, and ANTX is recording an average volume of 149.42K. On a monthly basis, the volatility of the stock is set at 3.72%, whereas on a weekly basis, it is put at 1.78%, with a gain of 1.80% over the past seven days. Furthermore, long-term investors anticipate a median target price of $1.67, showing growth from the present price of $1.13, which can serve as yet another indication of whether ANTX is worth investing in or should be passed over.

How Do You Analyze AN2 Therapeutics Inc Shares?

The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 34.12%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 36.69% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

ANTX shares are owned by institutional investors to the tune of 36.69% at present.

Hot this week

Nurix Therapeutics Inc (NRIX)’s stock price in review: A technical analysis

While Nurix Therapeutics Inc has underperformed by -0.34%, investors...

A closer look at EON Resources Inc (EONR)’s stock price trends

While EON Resources Inc has underperformed by -0.60%, investors...

Brazil Potash Corp (GRO)’s stock rises to 1.9 per share

While Brazil Potash Corp has overperformed by 11.11%, investors...

Adaptive Biotechnologies Corp (ADPT) stock analysis: A comprehensive overview

While Adaptive Biotechnologies Corp has underperformed by -2.07%, investors...

Ardelyx Inc (ARDX)’s stock price range in the last year

While Ardelyx Inc has underperformed by -1.40%, investors are...

Topics

Nurix Therapeutics Inc (NRIX)’s stock price in review: A technical analysis

While Nurix Therapeutics Inc has underperformed by -0.34%, investors...

A closer look at EON Resources Inc (EONR)’s stock price trends

While EON Resources Inc has underperformed by -0.60%, investors...

Brazil Potash Corp (GRO)’s stock rises to 1.9 per share

While Brazil Potash Corp has overperformed by 11.11%, investors...

Adaptive Biotechnologies Corp (ADPT) stock analysis: A comprehensive overview

While Adaptive Biotechnologies Corp has underperformed by -2.07%, investors...

Ardelyx Inc (ARDX)’s stock price range in the last year

While Ardelyx Inc has underperformed by -1.40%, investors are...

Teladoc Health Inc (TDOC) stock: A year of ups and downs

While Teladoc Health Inc has underperformed by -8.17%, investors...

How to interpret Reddit Inc (RDDT)’s stock chart patterns

While Reddit Inc has underperformed by -4.45%, investors are...

Quantum Corp (QMCO) stock on the rise: An overview

While Quantum Corp has underperformed by -4.83%, investors are...
spot_img

Related Articles

Popular Categories

spot_imgspot_img
US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.